征祥医药递表港交所

Group 1 - Zhengxiang Pharmaceutical (Nanjing) Group Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) as its sole sponsor [1] - Zhengxiang Pharmaceutical is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies to address unmet medical needs in the fields of viral infectious diseases, oncology, and inflammatory diseases [1] Group 2 - The core product of Zhengxiang Pharmaceutical, Marcilosavir tablets, is an inhibitor targeting the influenza virus polymerase acidic protein (PA) endonuclease, which received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) in July 2025 for the treatment of adult influenza [4] - The company is expanding the indications of Marcilosavir to include adolescent patients and post-exposure prophylaxis [4] - Zhengxiang Pharmaceutical has developed a pipeline of six drug assets, including the commercialized Marcilosavir tablets, a clinical late-stage Marcilosavir suspension for pediatric influenza patients, and ZX-8177 for solid tumors in phase I clinical trials, along with ZX-12042B for human papillomavirus (HPV) infection currently in the IND application stage [4] - Additionally, the company has two clinical candidates for herpes simplex virus (HSV) infections and autoimmune diseases in preclinical stages [4]